Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ensitrelvir Fumaric Acid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Recipient : Shionogi
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, the 7 selected generic manufacturers will manufacture and supply Xocova (ensitrelvir fumaric acid), an oral antiviral drug for COVID-19 recently approved in Japan, in 117 low and middle income countries.
Brand Name : Xocova
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 26, 2023
Lead Product(s) : Ensitrelvir Fumaric Acid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Shionogi
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
